TWI328039B - - Google Patents
Download PDFInfo
- Publication number
- TWI328039B TWI328039B TW94114770A TW94114770A TWI328039B TW I328039 B TWI328039 B TW I328039B TW 94114770 A TW94114770 A TW 94114770A TW 94114770 A TW94114770 A TW 94114770A TW I328039 B TWI328039 B TW I328039B
- Authority
- TW
- Taiwan
- Prior art keywords
- swine fever
- fever virus
- glycoprotein
- recombinant
- protein
- Prior art date
Links
- 241000710777 Classical swine fever virus Species 0.000 claims description 109
- 210000004027 cell Anatomy 0.000 claims description 89
- 108090000623 proteins and genes Proteins 0.000 claims description 70
- 108090000288 Glycoproteins Proteins 0.000 claims description 61
- 102000003886 Glycoproteins Human genes 0.000 claims description 61
- 102000004169 proteins and genes Human genes 0.000 claims description 55
- 241000282898 Sus scrofa Species 0.000 claims description 51
- 241000700605 Viruses Species 0.000 claims description 48
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 46
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 45
- 229960005486 vaccine Drugs 0.000 claims description 18
- 239000000710 homodimer Substances 0.000 claims description 15
- 230000004927 fusion Effects 0.000 claims description 14
- 241000238631 Hexapoda Species 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 210000004881 tumor cell Anatomy 0.000 claims description 7
- 230000028993 immune response Effects 0.000 claims description 6
- 238000002255 vaccination Methods 0.000 claims description 6
- 101900173079 Classical swine fever virus Envelope glycoprotein E2 Proteins 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 102000029797 Prion Human genes 0.000 claims 1
- 108091000054 Prion Proteins 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 241000282887 Suidae Species 0.000 description 35
- 241000701447 unidentified baculovirus Species 0.000 description 35
- 206010037660 Pyrexia Diseases 0.000 description 26
- 101710125507 Integrase/recombinase Proteins 0.000 description 22
- 230000003053 immunization Effects 0.000 description 22
- 238000000034 method Methods 0.000 description 22
- 238000002649 immunization Methods 0.000 description 20
- 238000001262 western blot Methods 0.000 description 20
- 230000003472 neutralizing effect Effects 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 16
- 238000001962 electrophoresis Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 238000001514 detection method Methods 0.000 description 13
- 239000000427 antigen Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 238000003752 polymerase chain reaction Methods 0.000 description 12
- 101150082674 E2 gene Proteins 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 10
- 108010076504 Protein Sorting Signals Proteins 0.000 description 9
- 230000000890 antigenic effect Effects 0.000 description 9
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 201000000050 myeloid neoplasm Diseases 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102100034349 Integrase Human genes 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 230000005875 antibody response Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 210000004180 plasmocyte Anatomy 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 101710091045 Envelope protein Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- 101710188315 Protein X Proteins 0.000 description 4
- 230000001174 ascending effect Effects 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 229940124590 live attenuated vaccine Drugs 0.000 description 4
- 229940023012 live-attenuated vaccine Drugs 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 241001118702 Border disease virus Species 0.000 description 3
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 3
- 101800001466 Envelope glycoprotein E1 Proteins 0.000 description 3
- 101710170453 Glycoprotein 55 Proteins 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 229960003896 aminopterin Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002480 immunoprotective effect Effects 0.000 description 3
- 239000003547 immunosorbent Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 210000002706 plastid Anatomy 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 229940031626 subunit vaccine Drugs 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 101800001137 E(rns) glycoprotein Proteins 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 101000707534 Homo sapiens Serine incorporator 1 Proteins 0.000 description 2
- 101000707474 Homo sapiens Serine incorporator 2 Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 101710155913 Major envelope protein Proteins 0.000 description 2
- 101710144111 Non-structural protein 3 Proteins 0.000 description 2
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000239226 Scorpiones Species 0.000 description 2
- 102100031707 Serine incorporator 1 Human genes 0.000 description 2
- 101710119335 Sliding-clamp-loader large subunit Proteins 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000002457 bidirectional effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 125000003147 glycosyl group Chemical group 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000009343 monoculture Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 101150067539 AMBP gene Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 238000011731 BALB/cByJ (JAX™ mouse strain) Methods 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 208000001613 Gambling Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 101000807236 Human cytomegalovirus (strain AD169) Membrane glycoprotein US3 Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710141347 Major envelope glycoprotein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101800000515 Non-structural protein 3 Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- MQMIOQSXPWPYPM-YKKWXZHHSA-N O=C1NC=NC2=C1NC=N2.O=C1NC(N)=NC2=C1NC=N2.OC[C@@H](O)[C@@H](O)[C@H](C=O)OP(O)(O)=O Chemical compound O=C1NC=NC2=C1NC=N2.O=C1NC(N)=NC2=C1NC=N2.OC[C@@H](O)[C@@H](O)[C@H](C=O)OP(O)(O)=O MQMIOQSXPWPYPM-YKKWXZHHSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 description 1
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000019897 UltracelTM Nutrition 0.000 description 1
- 101710100170 Unknown protein Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 102000054439 human MMP9 Human genes 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000012760 immunocytochemical staining Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW094114770A TW200639254A (en) | 2005-05-06 | 2005-05-06 | The recombinant classical swine fever virus glycoproteins E2, its monoclonal antibody and the use as the diagnostic reagent and subunit marker vaccine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW094114770A TW200639254A (en) | 2005-05-06 | 2005-05-06 | The recombinant classical swine fever virus glycoproteins E2, its monoclonal antibody and the use as the diagnostic reagent and subunit marker vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200639254A TW200639254A (en) | 2006-11-16 |
| TWI328039B true TWI328039B (ja) | 2010-08-01 |
Family
ID=46551308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW094114770A TW200639254A (en) | 2005-05-06 | 2005-05-06 | The recombinant classical swine fever virus glycoproteins E2, its monoclonal antibody and the use as the diagnostic reagent and subunit marker vaccine |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TW200639254A (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108530532A (zh) * | 2018-04-13 | 2018-09-14 | 吉林大学 | 猪瘟病毒单克隆抗体hk 44及医用用途 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI490229B (zh) * | 2011-12-22 | 2015-07-01 | Nat Univ Chung Hsing | 豬瘟病毒封套醣蛋白Ｅｒｎｓ之特異性單株抗體ＣＷ８１３及其於間接三明治ＥＬＩＳＡ抗體檢測之應用 |
| CN107936116A (zh) * | 2018-01-16 | 2018-04-20 | 河南牧业经济学院 | 高效价抗csfv单克隆抗体的制备方法 |
-
2005
- 2005-05-06 TW TW094114770A patent/TW200639254A/zh not_active IP Right Cessation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108530532A (zh) * | 2018-04-13 | 2018-09-14 | 吉林大学 | 猪瘟病毒单克隆抗体hk 44及医用用途 |
| CN108530532B (zh) * | 2018-04-13 | 2021-04-27 | 吉林大学 | 猪瘟病毒单克隆抗体hk 44及医用用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| TW200639254A (en) | 2006-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI508974B (zh) | 豬第二型環狀病毒(Porcine Circovirus Type 2)、含彼之免疫組合物、檢測套組及其應用 | |
| JP6178336B2 (ja) | ブタ生殖器呼吸器症候群（ｐｒｒｓ）の有効な制御のための合成ペプチドベースのマーカーワクチン及び診断システム | |
| CN106456741B (zh) | 包含e2蛋白tav表位中的取代的重组经典猪瘟病毒(csfv) | |
| Zhang et al. | Glycoprotein E2 of classical swine fever virus expressed by baculovirus induces the protective immune responses in rabbits | |
| Leifer et al. | Modified live marker vaccine candidate CP7_E2alf provides early onset of protection against lethal challenge infection with classical swine fever virus after both intramuscular and oral immunization | |
| Qin et al. | Identification of novel T-cell epitopes on infectious bronchitis virus N protein and development of a multi-epitope vaccine | |
| WO2018176075A1 (en) | Chimeric insect-specific flaviviruses | |
| Kumar et al. | Evaluation of surface glycoproteins of classical swine fever virus as immunogens and reagents for serological diagnosis of infections in pigs: A recombinant Newcastle disease virus approach | |
| Hua et al. | The immunogenicity of the virus-like particles derived from the VP2 protein of porcine parvovirus | |
| JP2022507053A (ja) | 新規ブタロタウイルス | |
| Kortekaas et al. | Rational design of a classical swine fever C-strain vaccine virus that enables the differentiation between infected and vaccinated animals | |
| AU2017380107B2 (en) | Isolation of a novel pestivirus causing congenital tremor A | |
| TWI328039B (ja) | ||
| Gyu-Jin et al. | Analysis of immune responses against nucleocapsid protein of the Hantaan virus elicited by virus infection or DNA vaccination | |
| Cao et al. | Classical swine fever virus C-strain with eight mutation sites shows enhanced cell adaptation and protects pigs from lethal challenge | |
| TWI393778B (zh) | Recombinant swine fever virus E2 glycoprotein, its single source antibody and its application in diagnostic reagents and subunit vaccines (2) | |
| US9315873B2 (en) | Marker vaccine for classical swine fever | |
| RU2765658C9 (ru) | Выделение нового пестивируса, вызывающего врожденный тремор а | |
| EP2230246A1 (en) | Arterivirus glycoprotein 5 virus-like particles | |
| Bidokhti et al. | Establishment of stably transfected cells constitutively expressing the full-length and truncated antigenic proteins of two genetically distinct mink astroviruses | |
| Sangewar | Improved vaccine platform for safe and effective control of Bovine Viral Diarrhea Virus | |
| JP2017141234A (ja) | ブタ生殖器呼吸器症候群（ｐｒｒｓ）の有効な制御のための合成ペプチドベースのマーカーワクチン及び診断システム | |
| US10138494B2 (en) | Whole expressed cell as antigen carrier, and use thereof in preparing vaccine or diagnostic agent, and screening monoclonal antibodies | |
| Dashprakash | MOLECULAR STUDIES ON BVDV-3 VIRUSES ORIGINATING FROM INDIAN CATTLE AND EVALUATION OF DIAGNOSTIC TESTS FOR THEIR DETECTION | |
| CN116731195A (zh) | 表达pedv s蛋白优势抗原区域的重组prrsv疫苗株的构建及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |